标题：Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
作者：Li, Xue; Lian, Zhen; Wang, Shuai; Xing, Ligang; Yu, Jinming
作者机构：[Li, Xue; Wang, Shuai] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Radiat Oncol, Tianjin 300060, Peoples R China.; [Li, Xue; Wan 更多
通讯作者：Xing, LG;Yu, JM
通讯作者地址：[Xing, LG; Yu, JM]Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250000, Shandong, Peoples R China.
关键词：Non-small cell lung cancer; Epidermal growth factor receptor; Programmed; cell death receptor/ligand 1; tyrosine kinase inhibitors
摘要：Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD-1/PD-L1) pathway displayed striking and durable clinical responses in patients with non-small-cell lung cancer (NSCLC). However, it is still undefined about the efficacy of PD-1/PD-L1 inhibitors in NSCLC patients with EGFR activating mutations. Preclinical studies indicate the immune modulatory effect of EGFR signaling by regulating expression of MHC I/II and PD-L1 on tumor cells and activity of lymphocytes. Thus, it might be practicable for the use of PD-1/PD-L1 inhibitors as monotherapy or combined with EGFR-TKIs in patients with EGFR activating mutations. In this review, we discussed the regulation effect of EGFR signaling on PD-1/PD-L1 pathway and the potential mechanisms behind combing EGFR-TKIs with PD-1/PD-L1 inhibitors. We also reviewed current available data on PD-1/PD-L1 inhibitors as monotherapy or combined with EGFR-TKIs in NSCLC with EGFR activating mutations, and explored possible factors influence its efficacy, which would be important considerations for future clinical trial designs. (C) 2018 Elsevier B.V. All rights reserved.